This study highlights the involvement of gene-body DNA methylation in regulating ONECUT2 expression, emphasizing that ONECUT2 gene-body DNA methylation can serve as a novel biomarker including needle biopsy samples and/or therapeutic target for aggressive PCa. This evidence concerns the gene ONECUT2 and posterior cortical atrophy.